Dynamic performance-based assessment for tied-arch bridges subjected to heavy multi-axial tractor-trailers

With rapid industrial development, the overloading of bridges caused by heavy multi-axle vehicles has become a critical problem worldwide. This work conducts a performance-based evaluation for tied-arch bridges subjected to heavy multi-axle vehicles, and a prediction function of the dynamic impact factor (DIF) for tied-arch bridges is proposed considering the bridge frequency, vehicle speeds, and road quality level. Specifically, the main parameters affecting the bridge response were first identified theoretically using a simplified multi-axle vehicle-bridge model. A tractor-trailer mechanical model and a tied-arch bridge model were subsequently constructed and coupled using displacement coordination conditions to explore the characteristics of the bridge response under heavy multi-axle tractor-trailers. Additionally, based on the identified factors, a detailed investigation of DIF was performed using the developed special vehicle-bridge interaction model. Finally, a suggested computational method for predicting DIF of tied-arch bridges was proposed. The results obtained indicate the impact effect of special tractor-trailers on bridges should not be ignored, even at low operating speeds and in good road conditions. Moreover, additional monitoring measures should be placed on the structural components that are sensitive to dynamic responses to regulate responses within an acceptable range.</p

MOESM3 of Tumor-infiltrating CD4+ T cells in patients with gastric cancer

Additional file 3: Figure S3. Effects of PD-1+ and Tim-3+ inhibition on IFN-Îł induction. (A) Flow cytometry results; (B) IFN-Îł induction on CD4+ cells

Table_1_Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis.docx

ObjectivePyrotinib and pertuzumab are effective treatment options for HER2-positive metastatic breast cancer (HER2+ MBC). Our study was to directly compare the efficacy and safety of pyrotinib plus trastuzumab (PyroH) and pertuzumab plus trastuzumab (HP) in patients with HER2+ MBC.MethodsWe conducted a retrospective examination of HER2+ MBC patients who received PyroH plus chemotherapy or HP plus chemotherapy between 2017 and 2022 at five institutions in China. Our primary endpoint was progression-free survival (PFS).ResultsThis study involved 333 patients, among which 161 received PyroH and 172 received HP. The utilization of PyroH as a first-line therapy for MBC was more prevalent among older patients, those with a shorter duration of disease-free interval, or those who had previously been treated with trastuzumab. Although in the first-line advanced treatment HP cohort showed numerically longer PFS (median PFS: 14.46 vs. 22.90 months, p=0.057), in the second-line or later treatments, there was no significant difference in PFS between the PyroH and HP groups (median PFS: 8.67 vs. 7.92 months, p=0.286). Despite HP showing a longer PFS in the overall cohort (median PFS: 9.30 vs. 13.01 months, p=0.005), it did not serve as an independent predictor of PFS in the multivariate analysis (HR 1.134, 95% CI 0.710-1.811, p=0.598). Without taxane, PyroH demonstrated a longer PFS than HP (median PFS: 10.12 vs. 8.15 months, p=0.017). PyroH group displayed a numerically longer median PFS in patients with brain metastases compared to the HP group, though not statistically significant (median PFS: 9.03 vs. 8.15 months, p=0.976). PyroH had higher incidence of grade 3/4 diarrhea (34.3% vs. 3.0%) but similar overall adverse events.ConclusionIn conclusion, PyroH is comparable in second-line or later treatment and during brain metastasis, even having superior efficacy without taxane in real-world setting. Toxicities were tolerable in both groups. (ClinicalTrials.gov: NCT05572645)</p

Image_1_Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis.pdf

ObjectivePyrotinib and pertuzumab are effective treatment options for HER2-positive metastatic breast cancer (HER2+ MBC). Our study was to directly compare the efficacy and safety of pyrotinib plus trastuzumab (PyroH) and pertuzumab plus trastuzumab (HP) in patients with HER2+ MBC.MethodsWe conducted a retrospective examination of HER2+ MBC patients who received PyroH plus chemotherapy or HP plus chemotherapy between 2017 and 2022 at five institutions in China. Our primary endpoint was progression-free survival (PFS).ResultsThis study involved 333 patients, among which 161 received PyroH and 172 received HP. The utilization of PyroH as a first-line therapy for MBC was more prevalent among older patients, those with a shorter duration of disease-free interval, or those who had previously been treated with trastuzumab. Although in the first-line advanced treatment HP cohort showed numerically longer PFS (median PFS: 14.46 vs. 22.90 months, p=0.057), in the second-line or later treatments, there was no significant difference in PFS between the PyroH and HP groups (median PFS: 8.67 vs. 7.92 months, p=0.286). Despite HP showing a longer PFS in the overall cohort (median PFS: 9.30 vs. 13.01 months, p=0.005), it did not serve as an independent predictor of PFS in the multivariate analysis (HR 1.134, 95% CI 0.710-1.811, p=0.598). Without taxane, PyroH demonstrated a longer PFS than HP (median PFS: 10.12 vs. 8.15 months, p=0.017). PyroH group displayed a numerically longer median PFS in patients with brain metastases compared to the HP group, though not statistically significant (median PFS: 9.03 vs. 8.15 months, p=0.976). PyroH had higher incidence of grade 3/4 diarrhea (34.3% vs. 3.0%) but similar overall adverse events.ConclusionIn conclusion, PyroH is comparable in second-line or later treatment and during brain metastasis, even having superior efficacy without taxane in real-world setting. Toxicities were tolerable in both groups. (ClinicalTrials.gov: NCT05572645)</p

A list of single nucleotide polymorphisms in candidate miRNA genes.

a<p>Entrez SNP reference ID(<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=np" target="_blank">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=np</a>).</p>b<p>Hardy-Weinberg equilibrium test was undertaken to calculate the <i>P</i> value, and <i>P</i><0.001 was considered not in accordance with Hardy-Weinberg equilibrium.</p

Baseline clinical characteristics of TNBC patients and controls.

a<p>Two-sided χ2 test.</p>b<p>First-degree relative or second-degree relative with breast cancer or ovarian cancer.</p

Organic–Inorganic Hybrid Glasses of Atomically Precise Nanoclusters

Organic–inorganic atomically precise nanoclusters provide indispensable building blocks for establishing structure–property links in hybrid condensed matter. However, robust glasses of ligand-protected nanocluster solids have yet to be demonstrated. Herein, we show [Cu4I4(PR3)4] cubane nanoclusters coordinated by phosphine ligands (PR3) form robust melt-quenched glasses in air with reversible crystal–liquid–glass transitions. Protective phosphine ligands critically influence the glass formation mechanism, modulating the glasses’ physical properties. A hybrid glass utilizing ethyldiphenylphosphine-based nanoclusters, [Cu4I4(PPh2Et)4], exhibits superb optical properties, including >90% transmission in both visible and near-infrared wavelengths, negligible self-absorption, near-unity quantum yield, and high light yield. Experimental and theoretical analyses demonstrate the structural integrity of the [Cu4I4(PPh2Et)4] nanocluster, i.e., iodine-bridged tetranuclear cubane, has been fully preserved in the glass state. The strong internanocluster CH−π interactions found in the [Cu4I4(PPh2Et)4] glass and subsequently reduced structural vibration account for its enhanced luminescence properties. Moreover, this highly transparent glass enables performant X-ray imaging and low-loss waveguiding in fibers drawn above the glass transition. The discovery of “nanocluster glass” opens avenues for unraveling glass formation mechanisms and designing novel luminescent glasses of well-defined building blocks for advanced photonics

PCR primers and probes of candidate SNPs of miRNAs.

<p>PCR primers and probes of candidate SNPs of miRNAs.</p

Organic–Inorganic Hybrid Glasses of Atomically Precise Nanoclusters

Organic–inorganic atomically precise nanoclusters provide indispensable building blocks for establishing structure–property links in hybrid condensed matter. However, robust glasses of ligand-protected nanocluster solids have yet to be demonstrated. Herein, we show [Cu4I4(PR3)4] cubane nanoclusters coordinated by phosphine ligands (PR3) form robust melt-quenched glasses in air with reversible crystal–liquid–glass transitions. Protective phosphine ligands critically influence the glass formation mechanism, modulating the glasses’ physical properties. A hybrid glass utilizing ethyldiphenylphosphine-based nanoclusters, [Cu4I4(PPh2Et)4], exhibits superb optical properties, including >90% transmission in both visible and near-infrared wavelengths, negligible self-absorption, near-unity quantum yield, and high light yield. Experimental and theoretical analyses demonstrate the structural integrity of the [Cu4I4(PPh2Et)4] nanocluster, i.e., iodine-bridged tetranuclear cubane, has been fully preserved in the glass state. The strong internanocluster CH−π interactions found in the [Cu4I4(PPh2Et)4] glass and subsequently reduced structural vibration account for its enhanced luminescence properties. Moreover, this highly transparent glass enables performant X-ray imaging and low-loss waveguiding in fibers drawn above the glass transition. The discovery of “nanocluster glass” opens avenues for unraveling glass formation mechanisms and designing novel luminescent glasses of well-defined building blocks for advanced photonics

Association between genotypes and TNBC risk.

a<p>Adjusted for age and smoking status.</p><p><i>P</i> trend : calculated by Cochran–Armitage trend test.</p